Peer AI, a leading agentic AI platform for life sciences regulatory documentation, has officially secured $12.1 million in a new round of financing.
Led by Flare Capital Partners and SignalFire, the round saw further participation coming from the likes of Greycroft, Atria, Alumni Ventures, Gaingels, and Mana Ventures, along with other strategic angel investors operating across the life sciences, healthcare, and technology industries.
“Our vision is to create an intelligent regulatory workflow that connects documentation, data, and decision-making to speed drug approvals,” said Anita Modi, CEO and co-founder of Peer AI. “Documentation drives every step of the drug development process. We’re putting agentic AI in the hands of expert medical writers to create documents faster, improve quality, and, ultimately, accelerate treatments to patients.”
To understand the significance of such a development, we must take into account how generating documentation for regulatory approval presently remains a critical drug development challenge. This is largely because drugs approval proposals require over 200,000 pages, spanning more than 1,500 unique documents.
In case that wasn’t enough, manual and fragmented processes also lead to missing data and discrepancies, often delaying approvals. As a result, nearly one-third of FDA submissions have quality issues, with regulators rejecting almost 75% of applications and causing, on an average, delays of around 435 days.
Against that, the Peer AI platform arrives on the scene bearing an ability to deploy purpose-built, domain-specific AI agents. Once deployed, these agents are combined with an intuitive AI-powered user interface. This makes it possible for medical writers to apply their subject matter expertise at critical control points during documentation workflows.
“We see enormous opportunity in GenAI-based tools to unlock value in drug discovery and clinical development processes, including automating the end-to-end process of regulatory documentation,” said Ian Chiang, partner at Flare Capital Partners. “Peer AI’s distinctive approach and specialized agentic AI platform are shaped by in-house medical writer expertise. They’re already demonstrating strong early client engagement and poised to become a category-defining platform.”
Talk about Peer AI’s technology on a slightly deeper level, we begin from its tendency to place agentic AI automation with strategic, easy to use human control points, all for the purpose of scaling AI-powered regulatory documentation efficiently with the highest level of integrity.
You see, the company’s medical writing agents, on their part, support experts big time in the context of multi-step document creation, as well as generating documents such as protocols, CSRs, investigational new drug (IND) applications, investigator’s brochures (IBs), and plain language summaries.
If we talk about data source agents, they can extract information from complex sources and ensure database integration. Moving on to authoring agents, they are able to create accurate drafts aligned with regulatory guidelines. Finally, style agents are tasked with ensuring compliant formatting, whereas post-processing agents perform final validation checks
Already, top 20 pharma and emerging biotechs are leveraging Peer AI’s proprietary technology to save thousands of hours and improve quality of regulatory documents across pre-clinical, clinical, regulatory affairs, and chemistry, manufacturing, and controls (CMC). Customers are also accelerating drafting times by 55–94%, while simultaneously cutting costs and improving consistency and accuracy.
Medical writing teams, for instance, have reduced clinical study report (CSR) drafting time from 40 to 17 working days, and at the same time, cut protocol turnaround from 6-8 weeks to just one week. Daily active use has also grown by 3X in the first three quarters of 2025, and alongside that, overall platform volume has increased 6X..
“The Peer AI team’s deep expertise across life sciences and AI uniquely positions them to drive greater efficiency in the entire drug development workflow,” said Sooah Cho, partner at SignalFire. “They’re establishing the foundational regulatory backbone for life sciences to transform a historically fragmented, manual process with a unified agentic platform and intuitive user experience that brings experts in the loop at the right times.”
